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reservation of Ischemic Myocardial
unction and Integrity With Targeted
ytoskeleton-Specific Immunoliposomes
ala Khudairi, PHD,*† Ban-An Khaw, PHD*
oston, Massachusetts
OBJECTIVES We sought to demonstrate preservation of myocardial function and integrity after targeted
cytoskeleton-specific immunoliposome (CSIL) treatment of globally ischemic Langendorff
instrumented hearts and a time response to treatment.
BACKGROUND Cell membrane lesion sealing of hypoxic cardiocytes in culture with CSIL has been reported.
METHODS Langendorff-perfused isolated rat hearts were subjected to global ischemia (25 min). Either
CSIL or placebo administration (1-min ischemia) was followed by 30 min of reperfusion.
Immunoglobulin G liposomes (IgG-L) or CSIL was also infused at 5, 10, and 20 min of
ischemia, reperfused, and then prepared for histochemical staining and electron microscopy.
RESULTS Recovery of left ventricular developed pressure (LVDP) of ischemic hearts treated with CSIL
at 1 min of ischemia, assessed at 5 min of reperfusion (98  14%), was similar to that of
sham-operated hearts (100%) but was significantly greater than that of placebo-treated hearts
(12  7%, p  0.01). The LVDP of hearts treated with CSIL at 5, 10, and 20 min was
significantly greater than that with IgG-L at corresponding times (p  0.03). Histochemical
integrity and ultra-structural myocardial integrity were consistent with the functional data.
CONCLUSIONS Preservation of myocardial viability ex vivo was achieved with CSIL therapy. The extent of
preservation is proportional to the time of initiation of therapy. Beneficial effects were
observed even when CSIL therapy was initiated at 20 min of global ischemia. Therefore,
delayed CSIL intervention after the onset of ischemia may augment preservation of
myocardial viability during reperfusion therapy. (J Am Coll Cardiol 2004;43:1683–9)























ihe major therapeutic goals of treating over one million
atients with acute myocardial infarction (AMI) annually
1) are to decrease morbidity and to decrease mortality.
iagnosis and treatment should optimally occur within 4 to
h of chest pain (2). Irreversible myocardial injury from
rolonged ischemia results in myocyte membrane lesions,
he hallmark of oncotic cell death (3). Thrombolytic therapy
r percutaneous transluminal coronary angioplasty can re-
tore perfusion but does not repair the membrane lesions of
he affected myocytes and is associated with concurrent
eperfusion injury (4,5). To reduce oncotic cell death asso-
iated with cell membrane lesions, we developed a method
o seal myocyte membrane lesions with (antimyosin)
ytoskeleton-specific immunoliposomes (CSIL) (6). Anti-
yosin antibody is highly specific for targeting myosin,
xposed through membrane lesions in the diagnosis of AMI
7,8), myocarditis (9), and heart transplant rejection (10).
Liposomes are bilayer lipid vesicles used in diagnosis,
ater-based ointments, gels in cosmetics, and drug and
ene delivery systems (11). Neutral liposomes are non-toxic
n serum (11). They can be made target-specific with
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Manuscript received May 22, 2003; revised manuscript received October 24, 2003,Accepted November 2, 2003.ntibodies (6). Thus, liposomes have been useful in biologic
pplications for several decades (11–15).
We hypothesized that lesions that developed in the
schemic myocardium would allow antimyosin on CSIL to
nchor to the exposed myosin, thus sealing the lesions,
ollowed by fusion of the liposomal lipid bilayer with the cell
embrane lipid bilayer (6,16). This should result in resto-
ation of cell membrane integrity and, if combined with
eperfusion, should lead to preservation of myocardial in-
egrity. The present study demonstrates that myocardial
reservation can be achieved in a time-dependent manner
ith CSIL therapy in an ex vivo model of globally ischemic
angendorff perfused rat hearts.
ETHODS
yosin-specific monoclonal 2G42D7, an immunoglobulin G
IgG)-1 murine antibody with an apparent affinity of 1 
09 l/mol (17,18), was produced in bioreactors (Cell-max
UAD, Cellco Inc., Laguna Hills, California), purified by
rotein A-affinity chromatography (19), and purity-assessed by
odium dodecyl sulfate polyacrylamide gel electrophoresis (X-
ell Surelock Mini-Cell with NuPage gel, 10% Bis-Tris,
nvitrogen, Carlsbad, California). The antibody activity was
ssessed by enzyme-linked immunosorbent assay (6,20).
odification of antibody. Antimyosin antibody was mod-
fied with N-glutaryl phosphatidyl ethanolamine (NGPE;
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Preservation of Ischemic Myocardium With CSIL May 5, 2004:1683–9g 2G4-2D7 in 2 ml of 137mmol/l NaCl, 2.7 mmol/l KCl,
.5 Na2HPO4, 1.4 mmol/l KH2PO4, at pH 7.4 (phosphate-
uffered saline [PBS]), was mixed with solid HEPES (24
g). Then, NGPE (0.3 mg) in 0.5 ml of 0.016 mol/l
ctyl-glucoside in 50 mmol/l of 2-N-morpholino ethane
ulfonic acid (pH 4.5) was activated with 12 mg of 1-ethyl-
-3-dimethylaminopropyl carbodiimide and 15 mg
-hydroxysulfosuccinimide and slowly added to the anti-
ody solution; pH was adjusted to 8.0 with 1 mol/l KOH
nd incubated overnight at 4°C with gentle stirring.
OPC-21 murine IgG1 was similarly modified.
mmunoliposome preparation. Unilamellar liposomes were
repared by the detergent dialysis method (22). Phosphatidyl
holine (30 mg) in chloroform and cholesterol (18 mg) (1:1
olar ratio) were dried for 2 h in a rotary evaporator. Two
illiliters of 50 mg octyl-glucoside/ml PBS were added to the
ry lipid film, stirred, and sonicated for 5 min. Next, NGPE/
ntimyosin or NGPE/MOPC-21 IgG was added, stirred, and
onicated (2 min), then dialyzed against 4 l PBS (pH 7.4)
vernight at 4°C. Resulting liposomes were extruded serially
hrough 0.8-, 0.45- (Millex, Bedford, Massachusetts), and
.2-m polycarbonate membrane syringe filters (6,16). The
ean (SD) diameter of the immunoliposomes was 200 35
m (Coulter N4 MD Submicron Particle Size Analyzer,
oulter Electronics, Miami, Florida).
angendorff perfused isolated hearts. The Langendorff
solated perfused heart model was used (23). The hearts of
D-1 male rats (250 to 300 g; n  4 each group, 34 total)
ere excised and perfused within 25 s with non-
ecirculating oxygenated Krebs-Henseleit bicarbonate buffer
120 mmol/l NaCl, 25 mmol/l NaHCO3, 1.2 mmol/l
gSO4 7H2O, 5 mmol/l KCl, 1.7 mmol/l CaCl 2H2O, 10
mol/l glucose, pH 7.4, 37°C) at a constant coronary
erfusion pressure (CPP) of 80 mm Hg. Each heart
mmersed in 0.9% NaCl at 37°C in a water-jacketed
hamber was paced at 300 beats/min (5 Hz). The left
entricular (LV) end-diastolic pressure was set at 10 mm
g, utilizing a water-filled balloon-tipped catheter attached
o a pressure transducer. Baseline hemodynamic measure-
ents were recorded on a strip-chart recorder (Hewlett-
ackard 7754A) for a 10-min stabilization period. Global
schemia (25 min) was initiated by decreasing the CPP to
ero within 60 s. A 2-ml aliquot of freshly prepared 1 mg
Abbreviations and Acronyms
AMI  acute myocardial infarction
CPP  coronary perfusion pressure
CSIL  cytoskeletal-specific immunoliposomes
IgG-L  immunoglobulin G liposomes
LV  left ventricle/ventricular
LVDP  left ventricular developed pressure
NBT  nitro blue tetrazolium
NGPE  N-glutaryl phosphatidyl ethanolamine
PBS  phosphate-buffered salineGPE/antimyosin/CSIL, 1 mg non-specific IgG lipo- Somes (IgG-L), or placebo (PBS) was infused at various
imes during ischemia. A 3-ml syringe was used to deliver
arious reagents via a three-way stopcock placed 8 cm above
he aorta, enabling injection without turning on the perfu-
ion pump, while maintaining the ischemic condition.
uring ischemia, the heart was paced for 5 min at zero CPP
o ensure adequate myocardial injury, then left unpaced for
0 min longer. Perfusion was restored to 80 mm Hg, and
acing was restarted at 3 min of reperfusion. Hemodynamic
easurements were recorded for 30 min of reperfusion.
earts were weighed, sectioned transversely (5 or 6 slices),
nd stained for 20 min in 0.05% nitro blue tetrazolium
NBT; Fisher Scientific, Fair Lawn, New Jersey) at 60°C
12). Sham-instrumented hearts underwent an identical
rocedure without ischemia.
This protocol was approved by the Institutional Animal
are and Use Committee, Northeastern University (Boston,
assachusetts) and conforms to the guidelines specified in the
ational Institutes of Health Guide for the Care and Use of
aboratory Animals.
ssessment of myocardial preservation. Myocardial func-
ion was assessed as the left ventricular developed pressure
LVDP)—the difference between the LV end-systolic and
iastolic pressures, measured at pre-ischemic, ischemic, and
ost-ischemic times (5, 10, 15, 20, 25, and 30 min of
eperfusion). The LVDP recovery during reperfusion was
alculated as the mean percent LVDP of the pre-ischemic
aseline values.
A single-blinded histochemical analysis was determined
y computer planimetry (Adobe Photoshop version 4.0) of
he digital photographs of NBT-stained heart slices. The
igital images were assigned numbers; the total and infarct
reas of the right ventricular and LV slices were quantitated
y computer planimetry after adjusting the brightness and
ontrast for optimal differentiation of the infarcted regions
Fig. 1A). The single-blinded code was broken, and infarct
izes were correlated to various treatments.
For ultra-structural assessment, a sample from the mid-
ortion of the LV of each heart was cut into smaller pieces
0.5 mm3); prefixed in 3% glutaraldehyde, 0.1 mol/l
odium acidulate, and 2% formaldehyde; postfixed in 1%
smium tetroxide and 0.1 mol/l sodium cacodylate; dehy-
rated in a graded series of ethanol; and embedded in
purr’s resin and polymerized overnight at 60°C. Ultra-thin
ections (gold-silver) were cut using a diamond knife (Du-
ont Company) and ultramicrotome (Reichert Ultracut E,
ustria), and the sections were contrasted with uranyl
cetate and lead citrate (24) and examined with a JEOL
JEM1010) transmission electron microscope.
Two micrographs each (6,000 magnification) from two
earts of each group were randomly obtained, and all
itochondria in the micrographs were quantitated by com-
uter planimetry. From each group, 225  12 (mean 
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May 5, 2004:1683–9 Preservation of Ischemic Myocardium With CSILtatistical analyses. Results are reported as the mean value
SEM. Wilcoxon rank-sum distribution (25) was used to
etermine significant differences of the mean values for all
tatistical comparisons in this report. Alpha was set at
0.05.
The LVDP of treatment groups (at 5 min of reperfusion,
r the overall mean value of individual mean LVDPs at 5,
0, 15, 20, 25, and 30 min of each group for total
ime-function curves) was compared. The same statistical
nalysis was employed in the time response study, the
omparison of single-blinded histochemical infarct sizes,
he mean mitochondrial sizes, and LVDP of hearts at the
lateau phase (between 20 and 30 min of reperfusion).
ESULTS
reatment at 1 min of ischemia. Treatment with CSIL
igure 1. (A) A digital photograph of a representative nitro blue tetrazo
nfarcted regions (top right), and an outline of the planimetered infarct a
LVDPs) (% pre-ischemic values) at 5 to 30 min of reperfusion after 25 min
CSIL) at 1 min of ischemia (CSIL 1’) (squares), PBS (open circles), or sh
f nitro blue tetrazolium-stained mid-slices of normal hearts (a) or heartsnitiated at 1 min of global ischemia resulted in functional fecovery in isolated rat hearts by 5 min of reperfusion. This
VDP (98 14%) was similar to that of sham controls, but
as greater than that of hearts treated with placebo (12 
%, p  0.01) (Fig. 1B).
The total time-function LVDP curves showed that recovery
fter CSIL treatment at 1 min of ischemia (87 6%) was not
ignificantly different from that of the sham group, but was
reater than that of placebo-treated hearts (12 2%, p 0.01).
The sufficiency of 25 min of global ischemia to induce
xtensive myocardial injury is demonstrated by the extensive
ack of NBT staining in heart slices of placebo controls (Fig.
C, panel c). Hearts treated with CSIL at 1 min of ischemia
ere almost normally stained on both the basal and apical
ides of the slices (Fig. 1C, panel b) and were similar to the
ntreated normal heart slices (Fig. 1C, panel a).
ime response. The mean LVDP of the total time-
stained heart slice (top left), a color-contrasted version to highlight the
or infarct sizing (bottom). (B) Mean left ventricular developed pressures
obal ischemia of hearts treated with cytoskeletal specific immunoliposomes
nstrumented hearts (solid circles). (C) Representative digital photographs
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Preservation of Ischemic Myocardium With CSIL May 5, 2004:1683–9f ischemia (77  3%, 70  12%, and 48  8%, respec-
ively) was less than that of the sham-operated hearts but
reater than that of IgG-L (44  7%, 58  4%, and 30 
%, respectively) or placebo-treated hearts (12  2%, p 
.01) (Figs. 2A to 2C).
A sequential delay of 5, 10, and 15 min in the recovery of
unction to near normal LVDP was observed in hearts
reated with CSIL at 1, 5, and 10 min of ischemia,
espectively (p  NS), but all LVPD values were greater
han those of hearts treated with CSIL at 20 min (p 
.05). The time-function curves for hearts treated with
SIL at 1 and 5 min of ischemia were greater than those at
0 min (p  0.01).
unctional assessment at 20 to 30 min of reperfusion. In
ll treated hearts, mean LVDP recovery reached a plateau by
0 min of reperfusion (Figs. 1B, 2A to 2C). The mean
lateau LVDP in hearts treated with CSIL at 5 and 10 min
f ischemia (87  3% and 87  4%, respectively) was
reater than that of the corresponding IgG-L controls (46
igure 2. (A) Mean left ventricular developed pressure (LVDP) during re
t 5 min of ischemia (CSIL 5’), immunoglobulin G liposomes (IgG-L)
nstrumentation. (B) Mean LVDP during reperfusion of hearts treated wi
ham. (C) Mean LVDP during reperfusion of hearts treated with CSIL o
hrough C) Sham  solid circles; CSIL  squares; IgG-L  triangles;
plateau phase) in hearts treated with CSIL, IgG-L, or PBS.6% and 68  3%, p  0.01 and 0.02, respectively). The alateau LVDP of hearts treated with CSIL at 20 min of
schemia (50 7%) was greater than that of IgG-L controls
29  5%), but was not statistically different (p  0.1);
owever, it was significantly greater than that of placebo
ontrols (15  4%, p  0.01) (Fig. 2D). No difference in
VDP was observed between hearts treated with CSIL at 5
nd 10 min of ischemia.
ingle-blinded histochemical assessment. Minimal un-
tained areas of the myocardium, indicative of minimal
njury, were observed in hearts treated with CSIL at 5 min
f ischemia (Fig. 3A, panel a). Myocardial injury increased
ith longer delays of CSIL treatment (at 10 and 20 min)
Fig. 3A, panels b and c). Hearts treated with IgG-L at 5,
0, and 20 min of ischemia (Fig. 3A, panels d to f) showed
ore extensive injury than did corresponding CSIL-treated
earts. Infarct sizes of hearts treated with IgG-L at 5, 10, or
0 min of ischemia (39  4%, 35  7%, and 45  6%,
espectively) were the same (Fig. 3B). Infarct sizes of hearts
reated with CSIL at 1, 5, and 10 min (4  1%, 8  3%,
ion of hearts treated with cytoskeletal specific immunoliposomes (CSIL)
min of ischemia (IgG-L 5’), phosphate buffered saline (PBS), or sham
IL or IgG-L at 10 min of ischemia (CSIL 10’ and IgG-L 10’), PBS, or
-L at 20 min of ischemia (CSIL 20’ and IgG-L 20’), PBS, or sham. (A
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SIL at 20 min (19 3%, p 0.05). Infarct sizes of hearts
reated with CSIL at 5, 10, and 20 min of ischemia were
maller than those treated with IgG-L at the corresponding
imes (Fig. 3B).
itochondrial size. The average size of normal mitochon-
ria (1,441  146 [mean number of pixels  SEM]) was
imilar to that of hearts treated with CSIL at 1, 5, 10, and
0 min of ischemia (1,496 103, 1,496 66, 1,845 147,
nd 1,504  101, respectively; p  NS) (Fig. 4). The mean
itochondria size of hearts treated with IgG-L at 5, 10, and
0 min of ischemia (2,294  95, 2,387  119, and 2,667 
7, respectively) or placebo (2,234  270) was greater than
igure 3. (A) Digital photographs of mid-slices of nitro blue tetrazolium-
tained hearts treated with cytoskeletal specific immunoliposomes (CSIL)
t 5 (a), 10 (b), and 20 (c) min of ischemia or immunoglobulin G liposomes
IgG-L) at 5 (d), 10 (e), and 20 (f) min of ischemia. (B) Mean infarct sizes
re expressed as the percentage of right and left ventricles of hearts treated
ith CSIL, IgG-L, phosphate buffered saline (PBS), or sham instrumen-
ation.hat of CSIL-treated hearts (p  0.05). 2ISCUSSION
he current study reports on the preservation of myocardial
iability in ex vivo adult ischemic hearts treated with CSIL.
reatment with CSIL initiated at 1 min of ischemia
esulted in apparent complete preservation of function,
iability, and mitochondrial integrity. A time-dependent
elationship between CSIL administration and myocardial
reservation was evident. This beneficial effect is maintained
ven when treatment was initiated at longer durations of
lobal ischemia. Thus, CSIL treatment need not be initi-
ted immediately but may be rendered subsequent to the
nset of AMI.
tudy design. In the coronary artery-occluded Langendorff
at heart model, irreversible injury occurred within 20 min
f ischemia (5). Disruption of the sarcolemma was observed
n canine hearts subjected to 15 (26,27) to 20 min of
oronary occlusion and reperfusion (28). The model of 25
in of global ischemia and 30 min of reperfusion was
hosen to provide more extensive irreversible myocardial
njury than the 20-min ischemia model. The extent of
yocardial injury is augmented by pacing the hearts for an
dditional 5 min during global ischemia, which resulted in
30% infarction of the total ventricles.
ssessment of myocardial preservation. The extent of
ecovery indicated by hemodynamic, histochemical, and
itochondrial ultra-structure indicates that myocardial
reservation after CSIL treatment was achieved.
unctional recovery. Preservation of myocardial viability
ith early CSIL treatment is consistent with clinical obser-
ations that maximal therapeutic benefits are associated
ith early intervention (29). This benefit persisted even
ith late administration of CSIL. However, there is a
ime-dependent delay in the recovery to near normal LVDP
ith a delay in the initiation of CSIL therapy (Figs. 1B, 2A,
nd 2B), which may be due to the need for more extensive
yocardial cell membrane lesion sealing. In isolated per-
used hearts, ventricular dysfunction may be due to myocar-
ial stunning or lethal cell injury (30). Recovery from
tunned to normal myocardium requires 24 to 48 h in the in
ivo reperfused heart with coronary artery occlusion of 2 to
igure 4. Mean pixel sizes of mitochondria in normal hearts, those treated
ith cytoskeletal specific immunoliposomes (CSIL) and immunoglobulin
liposomes (IgG-L) at various times after initiation of ischemia, and
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Preservation of Ischemic Myocardium With CSIL May 5, 2004:1683–9denosine triphosphate (ATP) to the myofibrils; injury of
he contractile apparatus; alterations in calcium homeostasis
ith calcium overload; and burst of free radicals (30). The
arliest consequence of severe ischemia is contractile dys-
unction, occurring within 6 to 10 s of ischemia (30). In the
angendorff perfused ischemic rat hearts, ATP concentra-
ions decrease rapidly to 60% in the first minute, with a
apid secondary decrease by 13 min due to contracture (32).
reatment with CSIL resulted in a rapid recovery of
unction; whether this is due to the reversal of myocardial
tunning must await further studies.
Greater functional recovery observed in IgG-L–treated
earts than in placebo hearts is not consistent with the
nfarct size data. The presence of IgG-L in the ischemic
yocardium may provide a non-specific mechanism of
ncreasing myocardial function. Dobrinina et al. (33)
howed that neutral liposomes preserved liver integrity in
ats subjected to hepatotropic poisons by non-specific
echanisms. However, histochemical infarct size data do
ot support this hypothesis (Fig. 3B). The liposomes of IgG
ay temporarily plug membrane lesions without fusion with
he cell membrane, ultimately leading to myocardial cell
eath, as determined by NBT. Nonetheless, the LVDP of
gG-L–treated hearts was still lower than that of CSIL-
reated hearts.
yocardial viability. Loss of tetrazolium staining after
schemic injury occurs due to loss of cofactor NADH and
nzymatic activity. The total NAD and NADH contents
re relatively stable in the early phases of ischemia but
ecrease after irreversible myocardial injury (30). Hearts
reated with CSIL at 1 min of ischemia were similar to
ham hearts that have minimal injury, a result of the
nsertion of the thebesian drainage port into the apex.
earts treated with CSIL at earlier times (1, 5, and 10 min)
howed extensive NBT staining, consistent with maximal
yocardial preservation. Hearts treated with CSIL at 20
in resulted in increased regions of negative NBT staining,
ndicating that myocardial recovery was not complete (Fig.
A, panel c). However, the extent of histochemical myo-
ardial injury was consistent with the extent of recovery of
unction in these hearts.
Similar to the recovery of LVDP of hearts treated with
SIL, NBT staining also indicated that there was greater
yocardial salvage in all hearts treated with CSIL than in
gG-L–treated controls (Fig. 3B).
ltra-structural morphologic integrity. Cessation of mi-
ochondrial electron transport has been observed 2 s after
he onset of global ischemia in isolated rat hearts (34).
ronounced mitochondria swelling with loss of cristae,
evelopment of amorphous matrix densities, and breaks in
he sarcolemma are seen in irreversibly injured myocytes
30). Increased mitochondrial size is an early indication of
schemia. In hearts with 3 to 15 min of ischemia, morpho-
ogic injury is reversible, yet some mitochondria remained
wollen even at 20 min of reperfusion (30). Therefore, a
ajority of the mitochondria in the ischemic myocardium is axpected to be edematous at 30 min of reperfusion. How-
ver, early CSIL treatment of ischemic hearts (1 and 5 min)
esulted in normal mitochondrial size, smaller than that of
SIL-treated hearts at later times. The results of mitochon-
rial size determination are compatible with the delay in the
ecovery of function with later administration of CSIL.
hus, mitochondrial ultra-structural data agree with the
unctional and histochemical data.
Preservation of cell membrane integrity after CSIL in-
ervention resulted in a faster recovery of function and a
eduction in infarct size. Whether this is associated with
revention of the influx of extracellular Ca2 that is asso-
iated with ischemia and reperfusion was not assessed in this
tudy. However, uncontrolled influx of Ca2 into the
ytosol occurs after reperfusion and results in rigor (35,36).
reatment with CSIL enabled globally ischemic hearts to
eturn to near normal function within 15 min of reperfu-
ion, which is consistent with the prevention of the occur-
ence of uncontrolled myocardial Ca2 overload. The ab-
ence of mitochondrial swelling and the return of function
o near normal in CSIL-treated hearts are also consistent
ith the maintenance of Ca2 homeostasis.
Cell membrane lesion sealing with neutral immunolipo-
omes may also reduce injury mediated by acid and oxidative
tress. However, plain liposomes in serum-free perfusate
ay augment this injury. Plain liposomes may mimic fatty
cids that inhibit enzymes, which may result in the uncou-
ling of oxidative phosphorylation. They may also act as
etergents, resulting in additional disruption of cell mem-
ranes (37).
tudy limitations. Our model of Langendorff perfused
earts used protein-free oxygenated perfusion buffer. It is a
on-working heart model; therefore, the ischemic myocytes
re not subjected to additional stresses. Furthermore, pro-
onged periods of reperfusion 30 min cannot be investi-
ated in this model, because of the inability to maintain
ong-term steady-state myocardial function ex vivo. Future
n vivo studies should permit investigation of prolonged
schemia and reperfusion with CSIL therapy.
The results presented may not necessarily imply that
SIL therapy may be beneficial in a clinical scenario of
MI. Furthermore, no conclusions can be drawn regarding
he impact of CSIL therapy on apoptotic myocardial cell
eath.
roposed mechanism of cell membrane lesion sealing.
lthough no direct ex vivo or in vivo evidence of cell
embrane lesion sealing was demonstrated in the current
tudy, the mechanism may be inferred from previous reports
6,16). Cardiocytes treated with fluorescent lipid-
ncorporated CSIL showed integration of the fluorescent
ipid into the cell membranes. Furthermore, fusion of CSIL
ith the cell membrane may be inferred from gene trans-
ection studies. Reporter genes entrapped in the intralipo-
omal cavities of CSIL successfully transfected hypoxic
ardiocytes. Only hypoxic cardiocytes treated with CSIL,
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May 5, 2004:1683–9 Preservation of Ischemic Myocardium With CSILn highly efficient gene transfection (16). Furthermore, if
reservation of myocardial viability were by non-specific
echanisms, IgG-L treatment should result in the same
xtent of myocardial salvage.
onclusions. This study supports the hypothesis that car-
iac cell membrane lesion sealing with CSIL resulted in
reservation of myocardial viability, as determined by func-
ion, histochemistry, and ultra-structural morphology.
here is also a time response to myocardial preservation
ith CSIL therapy. Early CSIL intervention after the onset
f ischemia resulted in almost complete myocardial recov-
ry. Even when the intervention was initiated at 20 min of
lobal ischemia, myocardial preservation was still greater
han that seen in hearts with IgG-L or placebo treatment.
herefore, CSIL therapy in AMI may result in beneficial
herapeutic outcome.
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